Literature DB >> 10452994

Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.

C S Schmidt1, M F Mescher.   

Abstract

CD8+ T cells from TCR transgenic 2C mice, specific for SIYRYYGL peptide bound to H-2Kb, were adoptively transferred into C57BL/6 recipients to allow monitoring of their location, numbers, and phenotype upon peptide challenge. Recipients were primed by s.c. injection of SIYRYYGL alone or with CFA or IL-12, and the transferred cells then tracked by flow cytometry using the 1B2 mAb specific for the 2C TCR. Peptide alone induced a transient and weak expansion of 1B2+ cells in the draining lymph nodes (DLN) by day 3, but these cells were tolerant to secondary peptide challenge. In contrast, priming with CFA/peptide resulted in a large clonal expansion of 1B2+ cells in DLN by day 3, and the cells exhibited a CD25highCD44high phenotype, blast transformation, and lytic effector function. By day 5, 1B2+ cell numbers decreased in the DLN and increased in the spleen and blood. 1B2+ cells with a memory phenotype persisted through day 60 in the DLN, spleen, and blood and responded to secondary peptide challenge. Immunization with peptide, along with IL-12, mimicked the adjuvant effects of CFA with respect to phenotype, clonal expansion, effector function, and establishment of memory. IL-12 was not unique in providing this adjuvant effect however, since CFA/peptide immunization of IL-12-deficient recipient mice also resulted in 1B2+ T cell activation and clonal expansion. Thus, CFA or IL-12 can enhance Ag-specific CD8+ T cell responses to peptide, demonstrating that an inflammatory cytokine(s) can support activation and prevent tolerance induction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452994

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 2.  Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation.

Authors:  Matthew F Mescher; Pujya Agarwal; Kerry A Casey; Christopher D Hammerbeck; Zhengguo Xiao; Julie M Curtsinger
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

3.  TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Authors:  Jason Z Oh; Jonathan S Kurche; Matthew A Burchill; Ross M Kedl
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

Review 4.  Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity.

Authors:  Derek B Danahy; Robert K Strother; Vladimir P Badovinac; Thomas S Griffith
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 5.  Inflammatory cytokines as a third signal for T cell activation.

Authors:  Julie M Curtsinger; Matthew F Mescher
Journal:  Curr Opin Immunol       Date:  2010-04-02       Impact factor: 7.486

6.  Programming for CD8 T cell memory development requires IL-12 or type I IFN.

Authors:  Zhengguo Xiao; Kerry A Casey; Stephen C Jameson; Julie M Curtsinger; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.

Authors:  Hilario J Ramos; Ann M Davis; Alexander G Cole; John D Schatzle; James Forman; J David Farrar
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 8.  Shaping successful and unsuccessful CD8 T cell responses following infection.

Authors:  Maureen A Cox; Allan J Zajac
Journal:  J Biomed Biotechnol       Date:  2010-03-31

9.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

10.  Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

Authors:  Malihe Naderi; Atefeh Saeedi; Abdolvahab Moradi; Mishar Kleshadi; Mohammad Reza Zolfaghari; Ali Gorji; Amir Ghaemi
Journal:  Virol Sin       Date:  2013-05-25       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.